# Sodium Nitroprusside in Early Course Schizophrenia

> **NCT04986072** · PHASE2 · TERMINATED · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 1 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder

## Interventions

- **DRUG:** Sodium Nitroprusside
- **DRUG:** 5% Dextrose solution

## Key facts

- **NCT ID:** NCT04986072
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-14
- **Primary completion:** 2024-06-01
- **Final completion:** 2024-07-01
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Difficulty with recruiting subjects for the study
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04986072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04986072, "Sodium Nitroprusside in Early Course Schizophrenia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04986072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*